Remdesivir and Renal Outcomes in Hospitalized COVID-19 Patients Without Severe Renal Impairment: A Retrospective Cohort Study
Remdesivir use was not associated with increased or reduced risk of RAEs in hospitalized COVID-19 patients without severe renal impairment, thereby supporting its continued clinical use as a safe antiviral without offering additional renal benefit.
Authors
- Sandra L. Kane‐Gill (ORCID: https://orcid.org/0000-0001-7523-4846)
- Na He (ORCID: https://orcid.org/0000-0002-2222-3876)
- Iman Karimzadeh (ORCID: https://orcid.org/0000-0002-8956-4528)
- Kangho Suh (ORCID: https://orcid.org/0000-0002-7906-9398)
- Xiaotong Li (ORCID: https://orcid.org/0000-0002-4622-0813)
Institutions
- University of Pittsburgh (US)
- Shiraz University of Medical Sciences (IR)
- Peking University (CN)
- Peking University Third Hospital (CN)
Publication Details
- Journal
- Annals of Pharmacotherapy
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1177/10600280251397359
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00